ClinicalTrials.gg
Drug

Lixisenatide clinical trials

Also written Lyxumia.

studies test it
57
open now
3
in phase 3
30
first study started
2006

How each study uses lixisenatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lixisenatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Jul 2016 · ADLYXIN · BLA 208471 (FDA, Drugs@FDA)
European Union
31 Jan 2013 · Lyxumia · EMEA/H/C/002445 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lixisenatide (AVE0010)
24
Lixisenatide
9
LIXISENATIDE AVE0010
4

Brand

Lyxumia
11

In one entry with another drug

Given together, or one or the other

iGlarLixi
9
Insulin glargine/Lixisenatide (HOE901/AVE0010)
7
Soliqua
4
Insulin glargine/Lixisenatide
3
LixiLan
3
Soliqua 100/33
2
HOE901/AVE0010
2

Studies by the year they started

57 studies that test it; most in 2008 (7)

Studies that test lixisenatide, by start year
YearStudies
20061
20087
20095
20104
20124
20135
20144
20153
20166
20173
20183
20194
20201
20211
20222
20231
20241
20252

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
6
Phase 3
30
Phase 4
14
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 41 · Other 16

Sanofi (40) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University Hospital, Toulouse (1) · Population Health Research Institute (1) · University of Campania Luigi Vanvitelli (1) · University Hospital, Gentofte, Copenhagen (1) · Seoul National University Hospital (1) · Medical University of Vienna (1)

Often tested with

Tested in the same studies.

Insulin Glargine (20) · Metformin (2) · IDegLira (1) · Liraglutide (1) · Dulaglutide (1)

Studies

Open first, then newest update. How each study uses lixisenatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 57

See all 57 studies that test lixisenatide →

Given beside what is tested · 1 — lixisenatide is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with lixisenatide

Codes

What other systems call lixisenatide · ClinicalTrials.gg INT004587

  • MeSH (NLM) C479460lixisenatideOne source NLM
  • UNII (FDA) 74O62BB01ULIXISENATIDEConfirmed FDA, NLM
  • RxNorm 1440051One source FDA
  • NCI Thesaurus C166988LixisenatideOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.